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Effects of growth hormone treatment on the pituitary expres- action. This GH insensitivity is partial, since treatment
sion of GHRH receptor mRNA in uremic rats. with high pharmacological doses of recombinant human
Background. A decreased ability of pituitary cells to secrete GH has been shown to accelerate growth velocity ofgrowth hormone (GH) in response to growth hormone releas-
uremic rats [1] and children with chronic renal failureing hormone (GHRH) stimulation has been shown in young
[2, 3]. Moreover, recent data from Haffner et al haveuremic rats. The aim of the current study was to examine
the effect of uremia and GH treatment on pituitary GHRH shown that sustained GH treatment is able to improve
receptor expression. the final height of adult patients with chronic renal insuf-
Methods. Pituitary GHRH receptor mRNA levels were ana- ficiency of pediatric onset [4].lyzed by RNase protection assay in young female rats made
The assumption of resistance to GH in renal failureuremic by subtotal nephrectomy, either untreated (UREM) or
is supported by the coexistence of growth retardationtreated with 10 IU/kg/day of GH (UREM-GH), and normal
renal function animals fed ad libitum (SAL) or pair-fed with and normal or high levels of circulating GH [5, 6]. Plasma
the UREM group (SPF). Rats were sacrificed 14 days after GH concentrations are physiologically influenced by pi-
the second stage nephrectomy.
tuitary secretion, which follows a pulsatile pattern, andResults. Renal failure was confirmed by concentrations (X
metabolic clearance rate. Analysis by deconvolution ofSEM) of serum urea nitrogen (mmol/L) and creatinine
(mol/L) in UREM (20  1 and 89.4  4.5) and UREM-GH plasma GH profiles allows the identification of secretory
(16  1 and 91.4  6.9) that were much higher (P  0.001) bursts [7], which is particularly important in renal failure
than those of sham animals (SAL, 3  0 and 26.5  2.2; SPF, since renal catabolism has been shown to account for 70%
4  0 and 26.5  2.1). UREM rats became growth retarded
of total catabolism of the hormone in rats [8]. In childrenas shown by a daily longitudinal tibia growth rate below (P 
with chronic renal failure, it has been found that the0.05) that observed in SAL animals (156  3 vs. 220  5 m/
day). GH treatment resulted in significant growth rate accelera- secretory component of GH peaks is normal [9] or de-
tion (213  6 m/day). GHRH receptor mRNA levels were pressed [10], whereas experimental studies have shown
no different among the SAL (0.43  0.03), SPF (0.43  0.08) abolition of GH pulses, prolonged GH half-life and markedand UREM (0.44  0.04) groups, whereas UREM-GH rats
reduction of GH secretion in stunted uremic rats [11].had significantly higher values (0.72  0.07).
In addition to the decreased GH secretion, the profoundConclusions. The status of pituitary GHRH receptor is not
modified by nutritional deficit or by severe uremia causing alteration of the pulsatile pattern observed in plasma of
growth retardation. By contrast, the growth promoting effect uremic rats may be important to explain growth impair-
of GH administration is associated with stimulated GHRH ment secondary to chronic renal failure. It is notable thatreceptor gene expression.
the amplitude of GH peaks has been shown to be posi-
tively correlated with growth velocity in male rats [12].
In agreement with a reduction of GH secretion inIt is believed that chronic renal failure generates a
chronic renal failure, in vitro perifusion studies havestate of peripheral resistance to growth hormone (GH)
demonstrated that the ability of dispersed pituitary cells
to release GH in response to growth hormone releasing
hormone (GHRH) stimulation is depressed in severelyKey words: chronic renal failure, uremia, growth hormone releasing
hormone, nutrition, growth promotion. uremic rats [13] in comparison with pair-fed rats with
normal renal function. This subnormal response is notReceived for publication January 28, 2002
caused by a lower relative number of GH-producing cellsand in revised form March 15, 2002
Accepted for publication April 10, 2002 [14]. Rather, analysis of dose-response curves suggests
that the decreased GH secretion in severe uremia may 2002 by the International Society of Nephrology
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be related to a lesser number of pituitary receptors for biochemical data were determined with a Kodak Ekta-
chemDT60 analyzer (Eastman Kodak, Rochester, NY,GHRH [13].
Therefore, the present experiment was designed to USA). Growth was assessed by weight gained between
days 11 and 18 and by determination of longitudinal bonestudy pituitary GHRH receptor gene expression in
growth-retarded uremic rats and to clarify the effect of growth rate over the last two days (see later in this article).
Food efficiency was calculated for each animal as therecombinant human GH treatment on such expression.
ratio between weight gained and food consumed (g/g)
and expressed as a percentage.
METHODS
Animals and experimental design Determination of longitudinal bone growth rate
Two days before sacrifice each animal received 20 mgFemale Sprague-Dawley rats aged 28  2 days and
weighing 100  5 g were obtained from the breeding per kilogram of body weight of tetracycline chlorhydrate
(Merck, Barcelona, Spain) intraperitoneally to label new-area of the animal facility building of the University of
Oviedo. Rats were housed in individual cages, main- bone mineralization.
Immediately after sacrifice, the proximal end of thetained at an environmental temperature of 22C and a
12-hour light-dark cycle. After three to five days of ac- tibiae including the growth plate were dissected out and
fixed in ethanol at 4C. Specimens were then dehydratedclimation to the experimentation area, the animals were
classified in the following groups of nine individuals each: in graded solutions of ethanol and embedded in methyl-
methacrylate. Ten-micrometer-thick frontal sections wererats with chronic renal failure, induced by 5/6 nephrec-
tomy, fed ad libitum (UREM); normal renal function obtained using a rotary microtome (Microm Interna-
tional, Walldorf, Germany) fitted with tungsten carbidesham-operated rats, fed ad libitum (SAL); normal renal
function sham-operated rats pair fed with UREM ani- blades. Sections were examined under a Leitz incident
light fluorescence microscope (Leica Microsistemas S.A.,mals (SPF); and chronic renal failure rats treated with
GH (UREM-GH). All animals had free access to tap Spain) and the distance between the chondro-osseous
junction and the proximal part of the tetracycline labelwater and received standard rat chow with a protein
content of 17.2% (A04; Panlab, Barcelona, Spain). was measured with an eyepiece micrometer at seven un-
biased locations on each section. The average value ofSubtotal nephrectomy or renal decapsulation without
loss of renal mass (sham operation) was performed in two these measurements divided by 2 (days) was considered
the longitudinal bone growth per day in each animal.stages on days 0 (excision of approximately 2/3 of the left
kidney, or decapsulation of the left kidney) and 4 (re-
Pituitary GHRH receptor mRNA expressionmoval of right kidney or only renal decapsulation). Surgi-
cal procedures were carried out under anesthesia with Anterior pituitaries from each rat were weighed and
three pituitaries of the same group were pooled for eachsodium thiopental (12.5 mg/kg Tiobarbital; B. Braun
Medical, Jaen, Spain) and ketamine chlorhydrate (40 experiment. Three experiments were performed for each
group. Total pituitary RNA was extracted using acidic phe-mg/kg, Ketolar; Parke Davis, Madrid, Spain) by intra-
peritoneal route. On day 18 of the protocol, the animals nol extraction of guanidine isothiocyanate lysate, accord-
ing to the method of Chomczinsky and Sacchi [15]. GHRHwere sacrificed under anesthesia and samples were col-
lected. Blood samples were stored at 20C until used, receptor gene expression was assessed by RNase protec-
tion assay, using a GHRH-R probe (cloned in pGEM-3Ztibiae were removed and processed as specified in this
article. Pituitary glands were immediately dissected out, plasmid; Promega Biotech, Madison, WI, USA) that en-
codes the 145-609 positions of the GHRH-R complemen-the neurointermediate lobe was carefully removed, and
the anterior pituitaries were stored at 70C until used. tary DNA (kindly provided by Dr. Gaylinn, University
of Virginia, USA). The antisense [32P]UTP-labeled probeA segment of liver also was obtained and immediately
frozen at 70C until its analysis. was generated by in vitro transcription of the Hind-III-
linearized plasmid pGEM-3Z, using the in vitro tran-The last week of the protocol (from days 11 to 17),
UREM-GH animals were treated with 10 IU/kg body scription kit SP6/T7 (Boehringer Manheim, Manheim,
Germany). RNase protection assays were performed us-weight (BW)/day of recombinant human GH (rhGH;
kindly supplied by Pharmacia & Upjohn, Stockholm, ing a kit (RPA II Kit; Ambion, Austin, TX, USA) es-
sentially as described by the manufacturer. For eachSweden) given in two intraperitoneal injections at 9.00
and 17.00 hours, approximately. The other three groups hybridization 20 g of total RNA were used. As an in-
ternal control, simultaneous hybridization with a labeledof rats received vehicle.
From day 4 on, animals and food were weighed daily probe of mouse -actin was performed for each assay.
Stable hybrids were separated on 6% polyacrylamide–8using an electronic balance (Ohaus GT 2100; Florham
Park, NJ, USA). The snout-to-tail length was measured mol/L urea gels. The gels were dried to X-ray film (Hy-
perfilm; Amersham S.A., Madrid, Spain) at 70C forwhen the rats were anesthetized (days 0, 4 and 18). Serum
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Table 1. Growth and food intake in the four groups of rats
SAL SPF UREM UREM-GH
(N  9) (N  9) (N  9) (N  9) P value
Day 0 weight g 99.51.1 99.10.9 98.91.1 99.10.7 NS
Day 0 length cm 28.50.2 28.90.1 29.00.1 28.70.2 NS
Weight gain g 28.92.6 17.93.0a,c 20.01.3a,c 32.62.5 0.05
Longitudinal growth rate lm/day 2205 1714a,b,c 1563a,c 2136 0.05
Food intake g 136.87.6 96.87.1a 96.87.1a 98.83.5a 0.001
Food efficiency % 21.21.7 18.63.0c 21.01.1c 32.72.0a 0.05
Data are mean  SEM. Abbreviations are: SAL, control rats fed ad libitum; SPF, control rats pair-fed with UREM; UREM, 5/6 nephrectomized rats; UREM-
GH, 5/6 nephrectomized rats treated with rhGH; NS, not statistically significant.
a P  0.05 compared with SAL
b P  0.05 compared with UREM
c P  0.05 compared with UREM-GH
48 hours (GHRH-R) or 24 hours (-actin). Liver tissue
was used as negative control to assess the specificity of
the GHRH-R probe. The quantification of the different
bands of the autoradiography was performed using the
TDI 1d Manager 2.0 software (T.D.I., Madrid, Spain).
The data were measured in arbitrary densitometric units
and are expressed as ratios of the readings of GHRH
receptor and its corresponding -actin band.
Statistical analysis
Results are given as mean SEM. Comparisons among
groups were performed by one-way analysis of variance
(ANOVA) followed by the Bonferroni test. A P value
0.05 was considered statistically significant.
RESULTS
Renal function
Renal failure of nephrectomized animals was con-
firmed by serum concentrations of urea nitrogen (UREM,
20 1 mmol/L; UREM-GH, 16 1 mmol/L) and creati-
nine (UREM, 89.4  4.5 mol/L; UREM-GH, 91.4 
6.9 mol/L) that were much higher (P  0.001) than
Fig. 1. (A) Levels (X  SEM) of growth hormone releasing hormonethose of sham animals (SAL, 3  0 mmol/L and 26.5 
(GHRH) receptor in the pituitaries of the four groups of animals.
2.2 mol/L; SPF, 4  0 mmol/L and 26.5  2.1 mol/L). Values, measured as arbitrary densitometric units, are expressed in
relation to the signal of the -actin band. (B) A representative experi-
ment is shown. Liver was used as negative control for hybridizationGrowth
with GHRH receptor probe. Abbreviations are: SAL, sham-operated
Data on growth and food intake are shown in Table 1. rats fed ad libitum; SPF, sham-operated rats pair-fed with the uremic
animals; UREM, uremic rats; UREM-GH, uremic rats treated withWeight and length of rats on day 0 were similar in the
recombinant human growth hormone (rhGH). Asterisk means signifi-different groups. The rats of UREM group were growth-
cantly different from the other groups.
retarded as shown by lower gain in body weight and
less longitudinal bone growth rate than sham animals.
UREM-GH rats gained more weight and had greater
food efficiency than the other three groups and their respectively. The relative pituitary weight of UREM-
GH rats was significantly (P  0.05) lower than that oflongitudinal bone growth rate was similar to that of SAL
animals, and greater than SPF and UREM rats. SAL animals.
Growth hormone releasing hormone receptor mRNA
Pituitary GHRH receptor mRNA expression expression was similar in the SAL (0.43  0.03), SPF
(0.43 0.08) and UREM (0.44 0.04) groups. However,The weights of the pituitaries, expressed in mg per
100 g BW, were 4.3  0.4, 3.3  0.2, 3.7  0.4, and 3.0  uremic rats treated with rhGH had increased GHRH
receptor mRNA levels (0.72  0.07, P  0.007; Fig. 1).0.1 in the SAL, SPF, UREM and UREM-GH groups,
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DISCUSSION in the study presented here, the mRNA pituitary levels
of the GHRH-receptor in young uremic rats were noRenal failure of the two groups of nephrectomized
different from those of animals with normal renal func-rats (UREM and UREM-GH) was severe and of similar
tion. This suggests that, at least at transcriptional level,degree as shown by serum concentrations of urea nitro-
chronic renal failure does not modify the GHRH recep-gen and creatinine much higher than those of sham-
tor mRNA expression in pituitary cells. However, ouroperated animals (SAL and SPF groups) and no different
data cannot rule out a defect in the post-transcriptionalbetween both groups. At the end of the study, UREM
regulation of the GHRH receptor gene expression ablerats became markedly growth retarded as confirmed by
to explain a potential reduction in the number of pitu-less weight gain and lower longitudinal bone growth rate
itary GHRH receptors.than SAL rats. To a large extent, the growth impairment
Our study also shows that the pituitary GHRH recep-of UREM rats was due to an associated nutritional deficit
tor mRNA levels in SPF rats were no different fromsince SPF rats also grew less than the SAL animals. As
those of the control animals fed ad libitum (SAL), indi-found in earlier studies using a similar experimental pro-
cating that the nutritional deficit did not influence the ex-tocol [1, 16], rhGH treatment accelerated the growth
pression of pituitary GHRH receptor mRNA. This find-rate of uremic rats, as demonstrated by greater weight
ing is in agreement with both the normal hypothalamicgain and greater longitudinal bone growth in UREM-GH
content of GHRH found by Bruno et al in malnourishedrats than in UREM animals. Improvement of growth was
rats [21] and the role of GHRH as regulator of the ex-associated with a better utilization of food and not with
pression of its own receptor. However, it should be keptan increased appetite, since food intake of UREM and
in mind that factors such as the intensity of malnutrition,UREM-GH rats was practically identical. This is consis-
the type of nutrient deficiency, either calories or proteins,tent with the well-known anabolic effect of GH adminis-
the duration of nutritional deficit, and the age and sextration.
of animals also are important modulators of the statusSeveral lines of evidence indicate that pulsatile secre-
of GHRH receptor [22–24]. Therefore, different experi-
tion of GH is coordinately regulated by the opposite ac-
mental conditions are likely to lead to different results.
tion of GHRH and somatostatin on pituitary cells [12]. An interesting finding of our study was that rhGH
Pituitary GHRH receptor plays a critical role in GH re- treatment markedly increased the GHRH receptor
lease, since it mediates the stimulating effect of GHRH mRNA concentrations in the pituitaries of uremic rats
on GH synthesis and secretion [17] as well as in growth, (group UREM-GH). To clarify the significance of this
since mutations of the peptide-binding domain have been finding, to our knowledge not previously reported in the
shown to profoundly disrupt body growth in mice [18]. literature, a complementary experiment following a pro-
Previous data from our group have indicated that chronic tocol like that of the present study was carried out to
renal failure modifies the normal pulsatile profile of se- analyze how pituitary GHRH receptor mRNA levels
rum GH in young rats, mainly as a result of a suppressed respond to rhGH administration in well nourished rats
GH secretion [11]. We also have shown a reduction of with normal renal function (data not shown). As ob-
in vitro GHRH-stimulated GH secretion in perifused served in the UREM-GH group, pituitary GHRH recep-
pituitary cells from severely uremic rats [13]. Moreover, tor mRNA levels increased approximately by 50% when
pharmacological analysis of the dose-response curves in compared with untreated animals, indicating that this
such study suggested a reduction of the population of effect occurs not only in uremia but also in normal ani-
GHRH receptors in the pituitary cells as the mechanism mals. To interpret this finding it should be kept in mind
responsible for the decreased ability of pituitary somato- that circulating GH as well as insulin-like growth factor-
trophs to secrete GH after GHRH stimulation. Of note, 1 (IGF-I) exert a negative feedback on GH secretion,
no change in the relative population of somatotrophs has stimulating or inhibiting the two hypothalamic peptides
been found in uremic rats [14], indicating that the de- somatostatin and GHRH, respectively [25]. Therefore, it
pressed release of GH is not secondary to a fewer num- can be hypothesized that elevated levels of GH, resulting
ber of GH secreting cells in the pituitary gland. In addi- from administration of high rhGH doses, might inhibit
tion, Metzger et al showed by in situ hybridization that GHRH release and this in turn would enhance the ex-
local GHRH gene expression in hypothalamus is re- pression of its pituitary receptor. The inhibitory effect
duced in moderate experimental chronic renal failure of exogenous rhGH administration on GHRH release
(CRF) [19]. Although the regulation of GHRH receptor is supported by the lower weight of pituitaries found in
is complex and far from being well understood, it is the UREM-GH rats since hypothalamic GHRH is
known that GHRH is an important regulator of GHRH known to exert a trophic effect on the pituitary gland
receptor mRNA expression [20]. Therefore, on the basis [26]. There are conflicting data on the regulation of pitu-
of all these findings it could be hypothesized that expres- itary GHRH receptor by GHRH, and direct [27, 28] and
inverse [29, 30] correlations between GHRH levels andsion of GHRH receptor was altered in uremia. However,
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analysis of spontaneous nocturnal growth hormone secretion inpituitary GHRH receptor expression have been found.
prepubertal children with preterminal chronic renal failure and
Multiple factors derived from a different experimental with end-stage renal disease. Pediatr Res 37:86–93, 1995
10. Schaefer F, Hamill G, Stanhope R, et al: Pulsatile growth hor-design may explain these differences. Miki et al have
mone secretion in peripubertal patients with chronic renal failure.shown that passive immunoneutralization of endogenous
Cooperative Study Group on Pubertal Development in Chronic
GHRH in male rats significantly increased the pituitary Renal Failure. J Pediatr 119:568–577, 1991
11. Garcia E, Santos F, Rodriguez J, et al: Impaired secretion ofmRNA levels of GHRH receptor, normalizing these lev-
growth hormone in experimental uremia. Relevance of caloricels after substitutive treatment with GHRH [30]. Our
deficiency. Kidney Int 52:648–653, 1997
results also support the concept that inhibition of GHRH 12. Muller EE, Locatelli V, Cocchi D: Neuroendocrine control of
growth hormone secretion. Physiol Rev 79:511–607, 1999release, likely induced by exogenous administration of
13. Rodriguez J, Santos F, Garcia de Boto MJ, et al: Severe uremiaGH, results in enhanced expression of pituitary GHRH
depresses the ability of perifused rat pituitary cells to secrete
receptor and that this effect is observed in uremic and growth hormone in response to growth hormone releasing hor-
mone. J Am Soc Nephrol 8:742–748, 1997normal rats.
14. Rodriguez J, Carbajo-Perez E, Santos F, et al: Severe experimen-In conclusion, the results of this study indicate that
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neither uremia nor malnutrition modify the pituitary totrophs. Nephrol Dial Transplant 13:2563–2565, 1998
15. Chomczynski P, Sacchi N: Single step method of RNA isolationmRNA expression of GHRH receptor in young rats.
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Anal Biochem 162:156–159, 1987
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Nephrol 6:262–266, 1992the neuroendocrine mechanisms that regulate GHRH
17. Mayo KE, Miller TL, De Almeida V, et al: The growth-hormone-
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